The table below is based on the pooled safety data on all LEMTRADA 12 mg-treated patients during all available follow up in clinical trials. Adverse reactions occurring in ≥% of patients are listed by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) and Preferred Term (PT). Frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions have been presented in order of decreasing seriousness.
Researchers have recently begun exploring the possibility that many well-known diseases have an immune component. Endocrine diseases like hypothyroidism or diabetes mellitus may be caused by immune rejection of hormone-producing cells. Kerratoconjunctivitis sicca (KCS or "dry eye") due to the shut-down of tear production responds to the antirejection drug cyclosporine. Chronic active hepatitis (liver disease) may also have an immune basis. These and many other areas of medicine are being explored for possible connection to the complicated world of autoimmune disease.